Matching articles for "dapagliflozin/metformin"
Drugs for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • November 4, 2019; (Issue 1584)
Diet, exercise, and weight loss can improve glycemic
control, but almost all patients with type 2 diabetes
eventually require drug therapy. Treating to a glycated
hemoglobin (A1C) concentration of...
Diet, exercise, and weight loss can improve glycemic
control, but almost all patients with type 2 diabetes
eventually require drug therapy. Treating to a glycated
hemoglobin (A1C) concentration of <7% can prevent
microvascular complications (retinopathy, nephropathy,
and neuropathy), but whether it prevents macrovascular
complications and death is unclear. An A1C target of
<8% may be appropriate for older patients and those
with underlying cardiovascular disease (CVD), a history
of severe hypoglycemia, diabetes-related complications,
a limited life expectancy, or a long duration of disease.
Invokamet and Xigduo XR - Two New Combinations for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • December 8, 2014; (Issue 1457)
The FDA has approved fixed-dose combinations of
metformin with either canagliflozin (Invokamet) or
dapagliflozin (Xigduo XR) for treatment of patients
with type 2 diabetes not adequately controlled
with any...
The FDA has approved fixed-dose combinations of
metformin with either canagliflozin (Invokamet) or
dapagliflozin (Xigduo XR) for treatment of patients
with type 2 diabetes not adequately controlled
with any one of these drugs, or in those already
being treated with both metformin and either
canagliflozin or dapagliflozin.